- Associated Press - Tuesday, February 16, 2016

NEW YORK (AP) - Zoetis Inc.’s fourth-quarter profit tumbled on a hefty charge for cutting operations in Venezuela, but the results still topped Wall Street expectations.

The maker of animal health and veterinary products saw profit fall 83 percent to $22 million, or 4 cents per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 43 cents per share. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 39 cents per share.

Revenue fell 3 percent to $1.27 billion in the period as a stronger dollar cut into international sales.

For the year, the Florham Park, New Jersey-based company reported profit of $339 million, or 68 cents per share. Revenue was reported as $4.76 billion.

Zoetis is the world’s biggest maker of medicines for pets and farm animals. It was spun off by Pfizer Inc. in 2013 and sells products including LymVax, a lyme disease vaccine for dogs and Revolution, which protects cats and dogs from fleas. In November, the company announced the $765 million purchase of privately-held Pharmaq, a maker of vaccines and other health products for aquaculture.

The acquisition helps boost the company’s position in the farmed fish market, which accounts for about half of all fish consumption. Pharmaq gives Zoetis a mix of vaccines, diagnostic products and parasite-killing drugs such as AlphaMax, which protects farmed salmon from sea lice.

Looking ahead, Zoetis expects full-year earnings in the range of $1.71 to $1.81 per share, with revenue in the range of $4.65 billion to $4.78 billion.

Zoetis shares rose 25 cents to $40.68 in afternoon trading Tuesday. Its shares have fallen 15 percent since the beginning of the year.


Elements of this story were generated by Automated Insights (https://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ZTS at https://www.zacks.com/ap/ZTS


Keywords: Zoetis, Earnings Report

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide